Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 2009, 27(36): 6199-6206.
Oda N, Ichihara E, Hotta K et al. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clin Lung Cancer, 2017, 18(2): 241-244.
Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1979, 63(11-12): 1727-1733.
Greaves M, Maley CC. Clonal evolution in cancer. Nature, 2012, 481(7381): 306-313.
Sun C, Wang L, Huang S et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508(7494): 118-122.
Johnson DB, Menzies AM, Zimmer L et al. Acquired BRAF inhibitor resistance: A multi-center meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer, 2015, 51(18): 2792-2799.
Romano E, Pradervand S, Paillusson A et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res, 2013, 19(20): 5749-5757.
Sanchez-Laorden B, Viros A, Girotti MR et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal, 2014, 7(318): ra30.
Johnson DB, Flaherty KT, Weber JS et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol, 2014, 32(33): 3697-3704.
Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. The Lancet Oncology, 2014, 15(9): 954-965.
Schreuer M, Jansen Y, Planken S et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol, 2017, 18(4): 464-472.
Roux J, Pages C, Malouf D et al. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. Melanoma Res, 2015, 25(6): 559-563.
Rogiers A, Wolter P, Bechter O. Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination. Melanoma Res, 2017, 27(2): 164-167.
Amann VC, Hoffmann D, Mangana J, Dummer R, Goldinger SM. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. J Eur Acad Dermatol Venereol, 2017.